Literature DB >> 8382610

Structure of Met30 variant of transthyretin and its amyloidogenic implications.

C J Terry1, A M Damas, P Oliveira, M J Saraiva, I L Alves, P P Costa, P M Matias, Y Sakaki, C C Blake.   

Abstract

Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant hereditary type of lethal amyloidosis involving single (or double) amino acid substitutions in the amyloidogenic protein transthyretin (TTR). The most common type of FAP (Type I, or Portuguese) is characterized by a Val-->Met substitution at position 30. The Met30 variant of TTR has been produced by recombinant methods, crystallized in a form isomorphous with native TTR, subjected to X-ray analysis and compared structurally with the wild-type protein. The comparison shows that the effect of the substitution at position 30 is transmitted through the protein core to Cys10, the only thiol group in the TTR subunit, which becomes slightly more exposed. The variant TTR molecule is otherwise in a near-native state. Use of computer graphics has shown that it is possible to model a linear aggregate of TTR molecules, each linked to the next by a pair of disulphide bonds involving Cys10 residues. Formation of these disulphide bonds involves a small number of slightly short molecular contacts with native TTR molecules, most of which are relieved in the Met30 variant. We propose this model as a possible basis for a molecular description of the FAP amyloid fibrils.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382610      PMCID: PMC413260          DOI: 10.1002/j.1460-2075.1993.tb05707.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  50 in total

1.  Isolation, characterization, cDNA cloning and gene expression of an avian transthyretin. Implications for the evolution of structure and function of transthyretin in vertebrates.

Authors:  W Duan; M G Achen; S J Richardson; M C Lawrence; R E Wettenhall; A Jaworowski; G Schreiber
Journal:  Eur J Biochem       Date:  1991-09-15

2.  Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO.

Authors:  T A Jones
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

3.  X-ray diffraction studies on amyloid filaments.

Authors:  E D Eanes; G G Glenner
Journal:  J Histochem Cytochem       Date:  1968-11       Impact factor: 2.479

4.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.

Authors:  C C Blake; M J Geisow; S J Oatley; B Rérat; C Rérat
Journal:  J Mol Biol       Date:  1978-05-25       Impact factor: 5.469

5.  Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (ILE-122).

Authors:  W C Nichols; J J Liepnieks; E L Snyder; M D Benson
Journal:  J Lab Clin Med       Date:  1991-03

6.  Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP).

Authors:  H Furuya; M J Saraiva; M A Gawinowicz; I L Alves; P P Costa; H Sasaki; I Goto; Y Sakaki
Journal:  Biochemistry       Date:  1991-03-05       Impact factor: 3.162

7.  Transthyretin Leu 68 in a form of cardiac amyloidosis.

Authors:  M R Almeida; A Hesse; A Steinmetz; B Maisch; K Altland; R P Linke; M A Gawinowicz; M J Saraiva
Journal:  Basic Res Cardiol       Date:  1991 Nov-Dec       Impact factor: 17.165

8.  Amyloid fibril protein in type I familial amyloidotic polyneuropathy in Japanese.

Authors:  S Tawara; S Araki; K Toshimori; H Nakagawa; S Ohtaki
Journal:  J Lab Clin Med       Date:  1981-12

9.  Restriction fragment analysis confirms the position 33 mutation in transthyretin from an Israeli patient (SKO) with familial amyloidotic polyneuropathy.

Authors:  D R Jacobson; F Santiago-Schwartz; J N Buxbaum
Journal:  Biochem Biophys Res Commun       Date:  1988-05-31       Impact factor: 3.575

10.  Vitreous amyloidosis associated with homozygosity for the transthyretin methionine-30 gene.

Authors:  O Sandgren; G Holmgren; E Lundgren
Journal:  Arch Ophthalmol       Date:  1990-11
View more
  16 in total

1.  Mutations in the B1 domain of protein G that delay the onset of amyloid fibril formation in vitro.

Authors:  Marina Ramírez-Alvarado; Melanie J Cocco; Lynne Regan
Journal:  Protein Sci       Date:  2003-03       Impact factor: 6.725

2.  A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis.

Authors:  D E Jenne; K Denzel; P Blätzinger; P Winter; B Obermaier; R P Linke; K Altland
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Binding of perlecan to transthyretin in vitro.

Authors:  S Smeland; S O Kolset; M Lyon; K R Norum; R Blomhoff
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

4.  Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation.

Authors:  N Schormann; J R Murrell; J J Liepnieks; M D Benson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

5.  Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor.

Authors:  Luís Gales; Sandra Macedo-Ribeiro; Gemma Arsequell; Gregorio Valencia; Maria João Saraiva; Ana Margarida Damas
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

6.  Inhibiting transthyretin amyloid fibril formation via protein stabilization.

Authors:  G J Miroy; Z Lai; H A Lashuel; S A Peterson; C Strang; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

Review 7.  Systemic amyloidoses.

Authors:  Luis M Blancas-Mejía; Marina Ramirez-Alvarado
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643

8.  Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis.

Authors:  Amareth Lim; Tatiana Prokaeva; Mark E McComb; Lawreen H Connors; Martha Skinner; Catherine E Costello
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

9.  Folding and aggregation of designed proteins.

Authors:  R A Broglia; G Tiana; S Pasquali; H E Roman; E Vigezzi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design.

Authors:  Isabel Cardoso; Maria Rosário Almeida; Nelson Ferreira; Gemma Arsequell; Gregorio Valencia; Maria João Saraiva
Journal:  Biochem J       Date:  2007-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.